Company / Operating Income
Phathom Pharmaceuticals, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$160.0M
FY2025
5-year range
-$172.4M / -$135.1M
FY2021-FY2025
Trend
+4.4%
vs FY2024
Sector context
#120 of 204
Health Care
What the data says
At -$160M, Phathom Pharmaceuticals, Inc.'s operating income ranks #120 of 204 in the Health Care sector. Improved from -$167M to -$160M over the past 2 years.
Based on SEC 10-K filings.
-$160M in FY2025.
Improved from -$167M to -$160M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#120 of 204 in Health CareTop 59% of 204This company -$160.0M Sector average $107.8M
▼
-248.5% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 4.4% year-over-year.
- Ranks #120 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$160.0M | +4.4% |
| FY2024 | -$167.3M | +0.0% |
| FY2023 | -$167.3M | +3.0% |
| FY2022 | -$172.4M | -27.7% |
| FY2021 | -$135.1M | -7.5% |
| FY2020 | -$125.7M | -18.3% |
| FY2019 | -$106.2M | -8570.6% |
| FY2018 | -$1.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026